)
iSpecimen (ISPC) investor relations material
iSpecimen Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Operates a technology-driven online marketplace connecting life science researchers with healthcare providers for the procurement of human biospecimens and associated data, aiming to streamline and scale the biospecimen supply chain globally.
Revenue is generated by sourcing specimens from a network of 55+ healthcare organizations in 14 countries and distributing them to research clients, with revenue sharing back to suppliers.
Products include remnant and research-use-only biofluids, tissues, and hematopoietic stem and immune cells, with a focus on just-in-time procurement rather than inventory banking.
Customers include biopharmaceutical, in vitro diagnostic, and government/academic institutions, with over 219,000 specimens distributed to 23 countries as of March 31, 2026.
The platform is being modernized to enhance automation, data integration, and scalability, with ongoing investments in technology and operational efficiency.
Financial performance and metrics
Reported net losses of $10.5 million in 2025 and $12.5 million in 2024, with an accumulated deficit of $84.6 million as of March 31, 2026.
Revenue for the three months ended March 31, 2026 was $1.93 million, compared to $2.69 million for the same period in 2025.
Cash balance as of March 31, 2026 was $2.8 million, with working capital of $814,038.
Revenue is highly concentrated, with one customer accounting for 54% of revenue in Q1 2026 and 20% in 2025.
The company is not currently profitable and expects to continue incurring losses for the foreseeable future.
Use of proceeds and capital allocation
Net proceeds from the offering will be used for placement agent fees, offering expenses, debt repayment, potential acquisitions, marketing (up to $1 million to IR Agency LLC), and general corporate and working capital purposes.
Management has broad discretion over the allocation of proceeds, and actual use may vary depending on business needs and market conditions.
- Biospecimen marketplace raises $2.5M in private placement; large resale may impact share price.ISPC
Registration filing4 Jun 2026 - Key votes include director election, auditor ratification, and a new stock incentive plan.ISPC
Proxy filing18 May 2026 - Q1 2026 revenue plunged 85% and net loss deepened, raising going concern risks.ISPC
Q1 202618 May 2026 - Meeting adjourned without business due to lack of quorum; reconvening details to follow.ISPC
AGM 20268 May 2026 - 2025 revenue fell 79% to $1.93M, net loss improved to $10.49M, but going concern risks persist.ISPC
Q4 20251 Apr 2026 - No quorum was present, so the meeting was adjourned without conducting any business.ISPC
AGM 202613 Mar 2026 - Director resignation prompts amendment to election proposal ahead of rescheduled annual meeting.ISPC
Proxy Filing3 Mar 2026 - Q2 2024 revenue up 76% to $2.86M, net loss narrowed, but going concern risks remain.ISPC
Q2 20242 Feb 2026 - No quorum was present, so the annual meeting was adjourned without conducting business.ISPC
AGM 20261 Feb 2026
Next iSpecimen earnings date
Next iSpecimen earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)